Evidence map›Paper›PMID 42223472›Full record

Observational studyHuman vaccines & immunotherapeutics2026

T-cell responses to primary SARS-CoV-2 vaccination in Down syndrome - From childhood to adulthood.

Lobke C M Hensen, Bianca M M Streng, Femke van Wijk, Stefan Nierkens, Joanne G Wildenbeest, Louis J Bont, Eveline M Delemarre, PRIDE study group

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lobke C M HensenDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Bianca M M StrengDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Femke van WijkCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Stefan NierkensCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Joanne G WildenbeestDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Louis J BontDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Eveline M DelemarreDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-4310-0998
PRIDE study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome (DS) is the most common genetic disorder worldwide and associated with high morbidity and mortality rates during the COVID-19 pandemic. For safety reasons, SARS-CoV-2 vaccine schedules and dosages were age-dependent, with children <12 years (y) receiving a lower dose than adolescents and adults. While we previously reported age-dependent antibody responses after SARS-CoV-2 vaccination in children with DS, cellular vaccine responses in this population remain insufficiently characterized. We evaluated vaccine-induced T-cell responses in children with DS following primary mRNA SARS-CoV-2 vaccination. We measured SARS-CoV-2-specific T-cell abundance (N = 40) and their interferon-gamma (IFNγ) production (N = 55) after spike antigen re-stimulation in participants aged 3-74 y. We found no significant difference in the re-activation of SARS-CoV-2-specific CD4

Indexed as

CD4-Positive T-LymphocytesCOVID-19COVID-19 VaccinesDown SyndromeSARS-CoV-2T-LymphocytesAdolescentAdultAntibodies, ViralBNT162 VaccineChildChild, PreschoolFemaleHumansInterferon-gammaMaleAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesInterferon-gammaSpike Glycoprotein, CoronavirusChildrenCOVID-19Down syndromeIFNγmRNA vaccineSARS-CoV-2T cells

Identifiers

PMID42223472
PMCPMC13228946

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.